Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.

Regional sympathetic activity can be studied in humans using electrophysiological methods measuring sympathetic nerve firing rates and neurochemical techniques providing quantification of noradrenaline spillover to plasma from sympathetic nerves in individual organs. Essential hypertension: Such measurements in patients with essential hypertension disclose activation of the sympathetic outflows to skeletal muscle blood vessels, the heart and kidneys, particularly in younger patients. This sympathetic activation, in addition to underpinning the blood pressure elevation, most likely also contributes to left ventricular hypertrophy, and to the commonly associated metabolic abnormalities of insulin resistance and hyperlipidaemia. Antihypertensive drugs, such as moxonidine, which act primarily by inhibiting the sympathetic nervous system, should have additional clinical benefits beyond those attributable to blood pressure reduction, in protecting against hypertensive complications. Obesity-related hypertension: Understanding the neural pathophysiology of hypertension in the obese has been difficult. In normotensive obesity, renal sympathetic tone is doubled, but cardiac noradrenaline spillover (a measure of sympathetic activity in the heart) is only 50% of normal. In obesity-related hypertension, there is a comparable elevation of renal noradrenaline spillover, but without suppression of cardiac sympathetics (cardiac sympathetic activity being more than double that of normotensive obese and 25% higher than in healthy volunteers). Increased renal sympathetic activity in obesity may be a 'necessary' cause for the development of hypertension (and predisposes to hypertension development), but apparently is not a 'sufficient' cause. The discriminating feature of the obese who develop hypertension is the absence of the adaptive suppression of cardiac sympathetic tone seen in the normotensive obese. Heart failure: In cardiac failure, the sympathetic nerves of the heart are preferentially stimulated. Noradrenaline release from the failing heart at rest in untreated patients is increased as much as 50-fold, similar to the level seen in the healthy heart during near-maximal exercise. Activation of the cardiac sympathetic outflow provides adrenergic support to the failing myocardium, but at a cost of arrhythmia development and progressive myocardial deterioration. Psychosomatic heart disease: No more than 50% of clinical coronary heart disease is explicable in terms of classical cardiac risk factors. There is gathering evidence that psychological abnormalities, particularly depressive illness, anxiety states, including panic disorder and mental stress, are involved here, 'triggering' clinical cardiovascular events, and possibly also contributing to atherosclerosis development. The mechanisms of increased cardiac risk attributable to mental stress and psychiatric illness are not entirely clear, but activation of the sympathetic nervous system seems to be of prime importance.

[1]  G. Jennings,et al.  Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.

[2]  A Ahlbom,et al.  Job decision latitude, job demands, and cardiovascular disease: a prospective study of Swedish men. , 1981, American journal of public health.

[3]  G. Jennings,et al.  Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. , 1998, Archives of general psychiatry.

[4]  N. Frasure-smith,et al.  Depression and 18-month prognosis after myocardial infarction. , 1995, Circulation.

[5]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[6]  M. Elam,et al.  Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. , 1997, Circulation.

[7]  P. Vokonas,et al.  Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. , 1994, Circulation.

[8]  H. Gavras,et al.  Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. , 1997, Hypertension.

[9]  G. Grassi,et al.  How to assess sympathetic activity in humans. , 1999, Journal of hypertension.

[10]  A. Dart,et al.  Antiadrenergic effect of chronic amiodarone therapy in human heart failure. , 1999, Journal of the American College of Cardiology.

[11]  M. Schroll,et al.  Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. , 1996, Circulation.

[12]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[13]  D. Zipes The long QT interval syndrome. A Rosetta stone for sympathetic related ventricular tachyarrhythmias. , 1991, Circulation.

[14]  S. Julius,et al.  The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. , 1992, Blood pressure.

[15]  C. Nemeroff,et al.  The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. , 1998, Archives of general psychiatry.

[16]  I. Meredith,et al.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. , 1991, The New England journal of medicine.

[17]  I. Meredith,et al.  Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. , 1990, Physiological reviews.

[18]  M. Rostrup,et al.  Awareness of high blood pressure increases arterial plasma catecholamines, platelet noradrenaline and adrenergic responses to mental stress. , 1991, Journal of hypertension.

[19]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[20]  J. Leor,et al.  Sudden Cardiac Death Triggered by an Earthquake , 1996 .

[21]  E. Rimm,et al.  Prospective study of phobic anxiety and risk of coronary heart disease in men. , 1994, Circulation.

[22]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[23]  K. Hagbarth,et al.  Manoeuvres affecting sympathetic outflow in human skin nerves. , 1972, Acta physiologica Scandinavica.

[24]  A. Mimran,et al.  Diabetic nephropathy in normotensive patients , 1990, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[25]  G. Jennings,et al.  Panic disorder: coronary spasm as a basis for cardiac risk? , 1998, The Medical journal of Australia.

[26]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[27]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[28]  P. Korner,et al.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.

[29]  G. Jennings,et al.  Adverse consequences of high sympathetic nervous activity in the failing human heart. , 1995, Journal of the American College of Cardiology.

[30]  E. Braunwald,et al.  MYOCARDIAL NOREPINEPHRINE CONCENTRATION IN MAN. EFFECTS OF RESERPINE AND OF CONGESTIVE HEART FAILURE. , 1963, The New England journal of medicine.

[31]  D. Eckberg Sympathovagal balance: a critical appraisal. , 1997, Circulation.

[32]  M. Esler MENTAL STRESS, PANIC DISORDER AND THE HEART , 1998 .

[33]  F. Sannajust,et al.  Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. , 1994, The American journal of cardiology.

[34]  M. Esler,et al.  The peripheral kinetics of norepinephrine in depressive illness. , 1982, Archives of general psychiatry.